What diseases are crizotinib capsules used as a targeted drug to treat?

Crizotinib capsules are mainly used to treat a specific type of non-small cell lung cancer patients whose tumor cells carry positive mutations of anaplastic lymphoma kinase (ALK) or ROS1.

1. ALKpositive non-small cell lung cancer: Crizotinib capsule is one of the first-choice drugs for the treatment of ALKpositive non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer, and ALK positive mutation is one of the important molecular subtypes. Crizotinib can precisely act on the ALK receptor and inhibit its overactivation, thus blocking the growth and spread of tumor cells.

2.ROS1positive non-small cell lung cancer: In addition to ALKpositive mutations, crizotinib capsules are also suitable for the treatment of ROS1positive advanced non-small cell lung cancer. ROS1 is a rare tyrosine kinase receptor whose mutations can also drive the growth of tumor cells. The inhibitory effect of crizotinib on ROS1 provides a new treatment option for these patients.

The mechanism of action of crizotinib capsules is mainly based on its targeting. It can specifically bind to ALK or ROS1 receptors and inhibit the tyrosine kinase activity of these receptors. This inhibitory effect not only slows down the proliferation of tumor cells, but also promotes the apoptosis of tumor cells, thereby achieving the purpose of treating tumors.

Clinical trial data show that crizotinib capsules are effective in treating ALK positive and ROS1Excellent performance in positive non-small cell lung cancer. It can significantly improve patients' survival and quality of life, while side effects are relatively controllable. However, like all drugs, crizotinib may also cause some adverse reactions, such as visual disturbances, digestive system reactions, etc. Therefore, physicians need to closely monitor patients' responses when using crizotinib and make dose adjustments or discontinuation as needed.